Novel Malaria Vaccine targeting Mosquito salivary proteins

**OCR Number:** OCR 6108

**Description:**

- Malaria is a worldwide infectious disease, causing over 1M deaths annually. RTS,S (Mosquirix™), the world’s only licensed malaria vaccine targets the circumsporozoite protein (CSP) and is only 27-46% effective.
- A novel vaccine approach targets mosquito saliva components. Mosquito saliva is injected into patients along with malaria parasite.
- Immunizing mice with antibodies against SG1L3, the lead mosquito salivary protein, showed substantial reduction of Plasmodium liver burden and parasitemia, when challenged with infected mosquito.
- **Intellectual property** – A provisional patent application has been filed


**PI:** Erol Fikrig

**Licensing Contact:** Lolahon Kadiri
lolahon.kadiri@yale.edu